Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Aug;43(8):938-942.
doi: 10.1002/cac2.12466. Epub 2023 Jul 18.

The MonarchE trial: improving the clinical outcome in HR+ /HER2- early breast cancer: recent results and next steps

François Bertucci  1   2 , Pascal Finetti  1 , Emilie Mamessier  1 , Alexandre De Nonneville  1   2
Affiliations
Comment

The MonarchE trial: improving the clinical outcome in HR+ /HER2- early breast cancer: recent results and next steps

François Bertucci et al. Cancer Commun (Lond). 2023 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Alexandre de Nonneville declares consulting fees by Gilead, Seagen, Lilly, and Novartis, payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events by Gilead, Daiichi Sankyo, and MSD, Support for attending meetings and/or travel by Gilead, Lilly, and Daiichi Sankyo. The other authors declare no competing interests.

Figures

FIGURE 1
FIGURE 1
MonachE results, DFS and sensitivity profiles of patients with HR+/HER2‐ eBC according to “low‐risk” and “high‐risk” defined by MonarchE clinical criteria and next issues. (A) MonarchE results. (B) Results Radar chart showing the 5‐year DFS and the percentage of patients predicted as sensitive to CDK4/6i (RBsig and E2Fregulon signatures) and ET (E2F4‐activation signature) in the “low‐risk” patients (green line) and the “high‐risk” patients (red line) as defined by MonarchE clinical criteria. The radar chart scale axes range from 40 to 60%, except for the 5‐year DFS axis, which ranges from 70 to 100%. *, P < 0.05, **, P < 0.01, ***, P < 0.001. (C) Several issues of research are still required in this setting. Abbreviations: eBC: early‐stage breast cancer; CDK4/6i, cyclin‐dependent kinases 4/6 inhibitors; ET, endocrine therapy; DFS, disease‐free survival; iDFS, invasive disease‐free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.
See this image and copyright information in PMC

Comment on

References

    1. Garutti M, Griguolo G, Botticelli A, Buzzatti G, De Angelis C, Gerratana L, et al. Definition of high‐risk early hormone‐positive HER2‐negative breast cancer: A consensus review. Cancers. 2022;14(8):1898. - PMC - PubMed
    1. Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, et al. Adjuvant palbociclib for early breast cancer: The PALLAS trial results (ABCSG‐42/AFT‐05/BIG‐14‐03). J Clin Oncol. 2022;40(3):282‐93. - PMC - PubMed
    1. Loibl S, Marme F, Martin M, Untch M, Bonnefoi H, Kim SB, et al. Palbociclib for residual high‐risk invasive HR‐positive and HER2‐negative early breast cancer‐the penelope‐b trial. J Clin Oncol. 2021;39(14):1518‐30. - PubMed
    1. Johnston SRD, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, et al. Abemaciclib plus endocrine therapy for hormone receptor‐positive, HER2‐negative, node‐positive, high‐risk early breast cancer (monarchE): Results from a pre‐planned interim analysis of a randomised, open‐label, phase 3 trial. Lancet Oncol. 2023;24(1):77‐90. - PMC - PubMed
    1. Slamon DJ, Fasching PA, Patel R, Verma S, Hurvitz SA, Chia SKL, et al. NATALEE: Phase iii study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (ebc). J Clin Oncol. 2019;37:TPS597–TPS597.

Publication types